Seelos Therapeutics, Inc. (SEELQ)
OTCMKTS · Delayed Price · Currency is USD
0.0001
+0.000099 (9,900.00%)
At close: Jun 1, 2026

Seelos Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingJun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Revenue
2.012.2---0.38
Revenue Growth
76.05%-----
Gross Profit
-18.44-27.91-58.62---22.19
Operating Income
-29.81-40.5-70.92-61.67-18.76-27.75
Net Income
4.09-37.88-73.53-66.05-19.1-51.26
Earnings Per Share
47.06-989.53-2654.72-2790.49-1638.45-
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingJun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Cash & Investments
0.29315.5378.7315.6610.26
Total Debt
10.1614.2320.1218.969.72-
Net Cash (Debt)
-9.86-11.23-4.5959.785.9410.26
Net Cash Growth
---906.67%-42.13%-
Net Cash Per Share
-113.46-293.39-165.662525.50509.35-

Cash Flow & CapEx

Fiscal YearTTMFY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingJun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Operating Cash Flow
-13.27-23.91-61.6-49-20.91-19.31
Free Cash Flow
-13.27-23.91-61.6-49-20.91-19.31
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingJun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Operating Margin
-1480.04%-1838.36%----7399.20%
Pretax Margin
203.13%-1719.56%----13668.00%
Profit Margin
203.13%-1719.56%----13668.00%

Valuation

Fiscal YearCurrentFY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingAug '26 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
PS Ratio
0.006.18---96.30